Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Rapid Commun Mass Spectrom ; 22(5): 657-64, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18257112

RESUMO

A method based on liquid-liquid extraction followed by high-performance liquid chromatography (HPLC) with positive ion electrospray ionization tandem mass spectrometry (ESI-MS/MS) detection was developed for the simultaneous determination of lopinavir (LPV) and ritonavir (RTV) in human blood, semen and saliva samples. The acquisition was performed in multiple reaction monitoring (MRM) mode, monitoring the transitions: m/z 629 > 447.1 for LPV, 721.18 > 268.02 for RTV and m/z 747.22 > 322.03 for the internal standard (IS). The limit of quantification was 1 ng/mL for both analytes in all matrices. The method was linear in the studied range (1-2000 ng/mL for LPV and 1-200 ng/mL for RTV), with r2 > 0.99 for each drug, and the run time was 4.5 min. The intra-assay precisions (%) were in the ranges of 0.1-14.2 (LPV) and 0.4-12.7 (RTV), the inter-assay precisions were in the ranges of 2.8-15.3 (LPV) and 1.1-12.8 (RTV) and the intra-and inter-assay recoveries were >85% for both drugs. The extraction efficiencies were 73.5-118.4% for LPV and 74.4-126.2% for RTV. The analytical method was applied to measure LPV and RTV concentrations in blood plasma (total and unbound fraction), saliva and semen of six HIV+ individuals under stable treatment with Kaletra soft gel capsules. The results were consistent with previously published data.


Assuntos
Fármacos Anti-HIV/sangue , Inibidores da Protease de HIV/sangue , Pirimidinonas/sangue , Ritonavir/sangue , Saliva/química , Sêmen/química , Espectrometria de Massas por Ionização por Electrospray/métodos , Espectrometria de Massas em Tandem , Fármacos Anti-HIV/farmacocinética , Cromatografia Líquida de Alta Pressão , Inibidores da Protease de HIV/farmacocinética , Humanos , Lopinavir , Masculino , Pirimidinonas/farmacocinética , Ritonavir/farmacocinética
2.
Pharmacogenomics ; 9(3): 267-76, 2008 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-18303963

RESUMO

INTRODUCTION: Interethnic admixture is a source of cryptic population structure that may lead to spurious genotype-phenotype associations in pharmacogenomic studies. We studied the impact of population stratification on the distribution of ABCB1 polymorphisms (1236C>T, 2677G>T/A and 3435C>T) among Brazilians, a highly admixed population with Amerindian, European and African ancestral roots. METHODS: Individual DNA from 320 healthy adults was genotyped with a panel of ancestry informative markers, and the proportions of African component of ancestry (ACA) were estimated. ABCB1 genotypes were determined by the single base extension/termination method. We describe the association between ABCB1 polymorphisms and ACA by fitting a linear proportional odds logistic regression model to the data. RESULTS: The distribution of the ABCB1 2677G>T/A and 3435C>T, but not the 1236C>T, SNPs displayed a significant trend for decreasing frequency of the T alleles and TT genotypes from White to Intermediate to Black individuals. The same trend was observed in the frequency of the T/nonG/T haplotype at the 1236, 2677 and 3435 loci. When the population sample was proportioned in quartiles, according to the individual ACA estimates, the frequency of the T allele and TT genotype at each locus declined progressively from the lowest (< 0.25 ACA) to the highest (> 0.75 ACA) quartile. Linear proportional odds logistic regression analysis confirmed that the odds of having the T allele at each locus decreases in a continuous manner with the increase of the ACA, throughout the ACA range (0.13-0.94) observed in the overall population sample. A significant association was also detected between the individual ACA estimates and the presence of the T/nonG/T haplotype in the overall population. CONCLUSION: Self-identification according to the racial/color categories proposed by the Brazilian Census is insufficient to properly control for population stratification in pharmacogenomic studies of ABCB1.


Assuntos
Membro 1 da Subfamília B de Cassetes de Ligação de ATP/genética , Genética Populacional , Polimorfismo Genético , Polimorfismo de Nucleotídeo Único , Subfamília B de Transportador de Cassetes de Ligação de ATP , Adulto , Sequência de Bases , Brasil , Primers do DNA , Éxons , Feminino , Genótipo , Humanos , Desequilíbrio de Ligação , Masculino , Dados de Sequência Molecular , Grupos Raciais/genética , Análise de Regressão
3.
Ther Drug Monit ; 28(2): 175-9, 2006 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-16628127

RESUMO

The concentrations of lopinavir and ritonavir in seminal and blood plasma and the seminal human immunodeficiency virus (HIV) viral load were quantified by HPLC and the Nuclisens assay, respectively, in a cross-sectional study of 16 HIV-1-infected Brazilian men under stable treatment with a lopinavir/ritonavir containing antiretroviral regimen. Semen and blood samples were collected on 2 occasions: at 6 to 60 minutes before ("trough"), and 5 to 6 hours after ("peak") ingestion of regular doses of lopinavir/ritonavir. Median seminal lopinavir levels were 120.6 ng/mL (range, <20-1481.8 ng/mL) and 233.1 ng/mL (range, 48.4-1133.4 ng/mL) at trough and peak points, respectively. The corresponding values for ritonavir were 9.2 ng/mL (range, <5-47 ng/mL) and 17.1 ng/mL (range, 6.6-66.7 ng/mL). The median concentrations of lopinavir and ritonavir in semen were, respectively, 1.9% to 3% and 3.7% to 4.4% of those measured in blood plasma samples collected within 30 minutes. HIV-1 viral load was detectable in the semen of 2 and in the blood of 6 of 16 patients. These results may have implications for drug-resistant HIV-1 evolution and transmission.


Assuntos
Infecções por HIV/tratamento farmacológico , Pirimidinonas/farmacocinética , Ritonavir/farmacocinética , Sistema Urogenital/metabolismo , Disponibilidade Biológica , Brasil , Estudos Transversais , Infecções por HIV/sangue , Infecções por HIV/virologia , Inibidores da Protease de HIV/sangue , Inibidores da Protease de HIV/farmacocinética , Inibidores da Protease de HIV/uso terapêutico , HIV-1/efeitos dos fármacos , HIV-1/crescimento & desenvolvimento , Humanos , Lopinavir , Masculino , Pirimidinonas/sangue , Pirimidinonas/uso terapêutico , Análise de Regressão , Ritonavir/sangue , Ritonavir/uso terapêutico , Sêmen/química , Sêmen/efeitos dos fármacos , Fatores de Tempo , Sistema Urogenital/efeitos dos fármacos , Carga Viral
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa